Zobrazeno 1 - 10
of 235
pro vyhledávání: '"S. Vozeh"'
A narrow therapeutic margin and poor predictability of plasma concentrations are the main reasons for drug level monitoring during aminoglycoside treatment. Gentamicin, tobramycin, amikacin and netilmicin can now be accurately and rapidly measured by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ab15283ad0ccfcfeeda56149adbcd4
http://doc.rero.ch/record/301650/files/8-suppl_A-37.pdf
http://doc.rero.ch/record/301650/files/8-suppl_A-37.pdf
Publikováno v:
European Journal of Clinical Pharmacology. 55:559-565
Mibefradil was approved as a novel calcium antagonist in Switzerland in 1996. Following its launch as an antihypertensive and anti-anginal agent, there were reports about serious pharmacokinetic and pharmacodynamic interactions occurring with other d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a88e8da84aa13a8a499a0f8ed37cc5a8
https://doi.org/10.1007/s002280050673
https://doi.org/10.1007/s002280050673
Publikováno v:
Therapeutic Drug Monitoring. 20:172-180
The predictive value of a two-compartment Bayesian feedback program for tobramycin dose optimization was retrospectively evaluated in 199 hospitalized patients and compared with that of a simple non-Bayesian one-compartment model. Before dose adjustm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c36073130ac3c5e01b97f09a7effb5
https://doi.org/10.1097/00007691-199804000-00007
https://doi.org/10.1097/00007691-199804000-00007
Autor:
Leon Aarons, Luc P. Balant, Jean-Louis Steimer, Malcolm Rowland, F Mentre, P Morselli, S. Vozeh
Publikováno v:
Clinical Pharmacokinetics. 30:81-93
Currently, there is an increasing focus on the implementation of pharmacokinetic-pharmacodynamic (PK-PD) studies and modelling as essential tools for drug development. Strategies involving specifically the population approach, which are based on rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08da7630846d948ac57db71b77e32d75
https://doi.org/10.2165/00003088-199630020-00001
https://doi.org/10.2165/00003088-199630020-00001
Autor:
Jean-Louis Steimer, P. L. Morselli, F. Mentré, Malcolm Rowland, Luc P. Balant, Leon Aarons, S. Vozeh
Publikováno v:
European Journal of Clinical Pharmacology. 49:251-254
An expert meeting to discuss issues relating to the design of population pharmacokinetic/pharmacodynamic (PK/PD) studies was held in Brussels in March 1995, under the auspices of the European Co-operation in Science and Technology (COST), Medicine (B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0eb1026546f445c470f0656ded8118b
https://doi.org/10.1007/bf00226323
https://doi.org/10.1007/bf00226323
Publikováno v:
British Journal of Clinical Pharmacology. 31:279-286
1. Population pharmacokinetic parameters of quinidine were determined based on 260 serum drug concentration measurements in 60 patients treated for arrhythmias with quinidine sulphate or quinidine bisulphate (Kinidin duriles) orally. 2. Quinidine kin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a48400811c1fa1e0e4ece90ace685b3
https://doi.org/10.1111/j.1365-2125.1991.tb05531.x
https://doi.org/10.1111/j.1365-2125.1991.tb05531.x
Publikováno v:
European Journal of Clinical Pharmacology. 38:509-513
The pharmacokinetics of oral and i.v. propafenone and its major metabolites have been investigated in 8 healthy subjects. The total body clearance of propafenone was 963 ml/min, the terminal half-life 198 min and its absolute bioavailability was 15.5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd4007f9c7571619783648c88595109c
https://doi.org/10.1007/bf02336693
https://doi.org/10.1007/bf02336693
Autor:
S, Vozeh
Publikováno v:
Praxis. 88(16)
To answer the question of the benefit and the cost/benefit ratio of the activities of a drug regulatory agency, the most important, clinically relevant "products" of a licensing authority in general, and the Swiss licensing authority (IKS) in particu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::719fe5cc0c8b8978a87b394c2e4e072f
https://pubmed.ncbi.nlm.nih.gov/10355335
https://pubmed.ncbi.nlm.nih.gov/10355335
Autor:
M. Marosi, J.H. Livingston, G. Bauer, Gerhard Luef, A.P. Jonville, Susan Anderson, S. Vozeh, E. Autret, Yvonne Mariasy, C. Billard, E.G.H. Lyall, P. Bertrand
Publikováno v:
The Lancet. 336:1125-1127
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::906719ffb14fb0f72b6055fd32a21be6
https://doi.org/10.1016/0140-6736(90)92599-d
https://doi.org/10.1016/0140-6736(90)92599-d
Autor:
L. Balant, S. Vozeh, Leon Aarons, F. Mentré, Jean-Louis Steimer, P. L. Morselli, Malcolm Rowland
Publikováno v:
Web of Science
An expert meeting to discuss population pharmacokinetic/pharmacodynamic software was held in Brussels in November 1993 under the auspices of the European Co-operation in Science and Technology (COST), Medicine (B1) programme. Recently developed stati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec9022b6337b0b6f50571514c0fa63c5
https://doi.org/10.1007/bf00191898
https://doi.org/10.1007/bf00191898